FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:BAZ1B-MET

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: BAZ1B-MET
FusionPDB ID: 9028
FusionGDB2.0 ID: 9028
HgeneTgene
Gene symbol

BAZ1B

MET

Gene ID

9031

8731

Gene namebromodomain adjacent to zinc finger domain 1BRNA guanine-7 methyltransferase
SynonymsWBSCR10|WBSCR9|WSTFCMT1|CMT1c|MET|Met|RG7MT1|cm1p|hCMT1|hMet
Cytomap

7q11.23

18p11.21

Type of geneprotein-codingprotein-coding
Descriptiontyrosine-protein kinase BAZ1BhWALp2transcription factor WSTFwilliams syndrome transcription factorwilliams-Beuren syndrome chromosomal region 10 proteinwilliams-Beuren syndrome chromosomal region 9 proteinmRNA cap guanine-N7 methyltransferaseRNA (guanine-7-) methyltransferasehcm1pmRNA (guanine-7-)methyltransferasemRNA (guanine-N(7)-)-methyltransferasemRNA cap methyltransferase
Modification date2020031320200329
UniProtAcc

Q9UIG0

Main function of 5'-partner protein: FUNCTION: Atypical tyrosine-protein kinase that plays a central role in chromatin remodeling and acts as a transcription regulator. Involved in DNA damage response by phosphorylating 'Tyr-142' of histone H2AX (H2AXY142ph). H2AXY142ph plays a central role in DNA repair and acts as a mark that distinguishes between apoptotic and repair responses to genotoxic stress. Essential component of the WICH complex, a chromatin remodeling complex that mobilizes nucleosomes and reconfigures irregular chromatin to a regular nucleosomal array structure. The WICH complex regulates the transcription of various genes, has a role in RNA polymerase I and RNA polymerase III transcription, mediates the histone H2AX phosphorylation at 'Tyr-142', and is involved in the maintenance of chromatin structures during DNA replication processes. In the complex, it mediates the recruitment of the WICH complex to replication foci during DNA replication. {ECO:0000269|PubMed:11980720, ECO:0000269|PubMed:15543136, ECO:0000269|PubMed:16603771, ECO:0000269|PubMed:19092802, ECO:0000269|PubMed:19234442}.

Q9H1A3

Main function of 5'-partner protein:
Ensembl transtripts involved in fusion geneENST idsENST00000339594, ENST00000404251, 
ENST00000436117, ENST00000495962, 
ENST00000539704, ENST00000318493, 
ENST00000397752, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score14 X 17 X 6=142814 X 18 X 10=2520
# samples 2027
** MAII scorelog2(20/1428*10)=-2.83592407425437
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(27/2520*10)=-3.22239242133645
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: BAZ1B [Title/Abstract] AND MET [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: BAZ1B [Title/Abstract] AND MET [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)BAZ1B(72912827)-MET(116435709), # samples:1
Anticipated loss of major functional domain due to fusion event.BAZ1B-MET seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BAZ1B-MET seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BAZ1B-MET seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BAZ1B-MET seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BAZ1B-MET seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
BAZ1B-MET seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
BAZ1B-MET seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
BAZ1B-MET seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF.
BAZ1B-MET seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
BAZ1B-MET seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
BAZ1B-MET seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneBAZ1B

GO:0006974

cellular response to DNA damage stimulus

19092802

HgeneBAZ1B

GO:0016572

histone phosphorylation

19092802

TgeneMET

GO:0006370

7-methylguanosine mRNA capping

27422871



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:72912827/chr7:116435709)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across BAZ1B (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across MET (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000339594BAZ1Bchr772912827-ENST00000397752METchr7116435709+3547910168968266
ENST00000339594BAZ1Bchr772912827-ENST00000318493METchr7116435709+1503910168968266

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000339594ENST00000397752BAZ1Bchr772912827-METchr7116435709+0.0005505120.99944943
ENST00000339594ENST00000318493BAZ1Bchr772912827-METchr7116435709+0.0015911220.99840885

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for BAZ1B-MET

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
BAZ1Bchr772912827METchr7116435709910248VVKEDEGRRESIMVLWRAPLGADDKR

Top

Potential FusionNeoAntigen Information of BAZ1B-MET in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BAZ1B-MET_72912827_116435709.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BAZ1B-METchr772912827chr7116435709910HLA-B44:03RESIMVLW0.99910.9553816
BAZ1B-METchr772912827chr7116435709910HLA-B27:07GRRESIMVL0.99850.5365615
BAZ1B-METchr772912827chr7116435709910HLA-B27:04GRRESIMVL0.99750.8421615
BAZ1B-METchr772912827chr7116435709910HLA-B27:02GRRESIMVL0.99720.6657615
BAZ1B-METchr772912827chr7116435709910HLA-B27:05GRRESIMVL0.99710.9062615
BAZ1B-METchr772912827chr7116435709910HLA-B27:04RRESIMVLW0.99080.7988716
BAZ1B-METchr772912827chr7116435709910HLA-B14:02GRRESIMVL0.98620.7314615
BAZ1B-METchr772912827chr7116435709910HLA-B14:01GRRESIMVL0.98620.7314615
BAZ1B-METchr772912827chr7116435709910HLA-B27:02RRESIMVLW0.98290.6075716
BAZ1B-METchr772912827chr7116435709910HLA-B27:05RRESIMVLW0.97710.8005716
BAZ1B-METchr772912827chr7116435709910HLA-B48:01GRRESIMVL0.88350.5063615
BAZ1B-METchr772912827chr7116435709910HLA-B15:10GRRESIMVL0.81030.6902615
BAZ1B-METchr772912827chr7116435709910HLA-B15:37GRRESIMVL0.56130.641615
BAZ1B-METchr772912827chr7116435709910HLA-B27:02GRRESIMVLW0.9990.5948616
BAZ1B-METchr772912827chr7116435709910HLA-B27:05RRESIMVLWR0.99840.763717
BAZ1B-METchr772912827chr7116435709910HLA-B27:02RRESIMVLWR0.99810.5412717
BAZ1B-METchr772912827chr7116435709910HLA-B27:04GRRESIMVLW0.99790.78616
BAZ1B-METchr772912827chr7116435709910HLA-B14:01EGRRESIMVL0.92250.8653515
BAZ1B-METchr772912827chr7116435709910HLA-B14:02EGRRESIMVL0.92250.8653515
BAZ1B-METchr772912827chr7116435709910HLA-B14:02DEGRRESIMVL0.9980.8638415
BAZ1B-METchr772912827chr7116435709910HLA-B14:01DEGRRESIMVL0.9980.8638415
BAZ1B-METchr772912827chr7116435709910HLA-B40:03RESIMVLW0.99930.5094816
BAZ1B-METchr772912827chr7116435709910HLA-C07:05RRESIMVL0.99880.9768715
BAZ1B-METchr772912827chr7116435709910HLA-B27:14GRRESIMVL0.9970.8742615
BAZ1B-METchr772912827chr7116435709910HLA-C07:95GRRESIMVL0.98810.7509615
BAZ1B-METchr772912827chr7116435709910HLA-C07:05GRRESIMVL0.98660.9662615
BAZ1B-METchr772912827chr7116435709910HLA-C07:27GRRESIMVL0.98210.9617615
BAZ1B-METchr772912827chr7116435709910HLA-C07:13GRRESIMVL0.97710.9279615
BAZ1B-METchr772912827chr7116435709910HLA-B27:14RRESIMVLW0.97640.7356716
BAZ1B-METchr772912827chr7116435709910HLA-B39:12GRRESIMVL0.97280.8705615
BAZ1B-METchr772912827chr7116435709910HLA-C07:29GRRESIMVL0.97150.9418615
BAZ1B-METchr772912827chr7116435709910HLA-C07:95RRESIMVLW0.95740.8178716
BAZ1B-METchr772912827chr7116435709910HLA-C07:80GRRESIMVL0.89410.9614615
BAZ1B-METchr772912827chr7116435709910HLA-C07:67GRRESIMVL0.89410.9614615
BAZ1B-METchr772912827chr7116435709910HLA-B27:03RRESIMVLW0.8580.8153716
BAZ1B-METchr772912827chr7116435709910HLA-C07:46GRRESIMVL0.85510.9253615
BAZ1B-METchr772912827chr7116435709910HLA-C07:19GRRESIMVL0.8340.8359615
BAZ1B-METchr772912827chr7116435709910HLA-C07:10GRRESIMVL0.79780.9708615
BAZ1B-METchr772912827chr7116435709910HLA-C07:19RRESIMVLW0.79080.8032716
BAZ1B-METchr772912827chr7116435709910HLA-B27:03GRRESIMVL0.77950.9247615
BAZ1B-METchr772912827chr7116435709910HLA-B14:03GRRESIMVL0.45210.5982615
BAZ1B-METchr772912827chr7116435709910HLA-C12:16GRRESIMVL0.10450.9672615
BAZ1B-METchr772912827chr7116435709910HLA-B27:14RRESIMVLWR0.99820.7284717
BAZ1B-METchr772912827chr7116435709910HLA-B27:03GRRESIMVLW0.98760.8684616
BAZ1B-METchr772912827chr7116435709910HLA-B27:03RRESIMVLWR0.96150.7883717
BAZ1B-METchr772912827chr7116435709910HLA-B27:06RRESIMVL0.99970.8237715
BAZ1B-METchr772912827chr7116435709910HLA-C07:01RRESIMVL0.99920.7722715
BAZ1B-METchr772912827chr7116435709910HLA-B44:13RESIMVLW0.99910.9553816
BAZ1B-METchr772912827chr7116435709910HLA-B44:26RESIMVLW0.99910.9553816
BAZ1B-METchr772912827chr7116435709910HLA-B44:07RESIMVLW0.99910.9553816
BAZ1B-METchr772912827chr7116435709910HLA-B27:06GRRESIMVL0.99850.8382615
BAZ1B-METchr772912827chr7116435709910HLA-B27:10GRRESIMVL0.99750.9168615
BAZ1B-METchr772912827chr7116435709910HLA-B27:08GRRESIMVL0.99710.8496615
BAZ1B-METchr772912827chr7116435709910HLA-B27:09GRRESIMVL0.99660.8857615
BAZ1B-METchr772912827chr7116435709910HLA-A68:02ESIMVLWRA0.99450.8398918
BAZ1B-METchr772912827chr7116435709910HLA-A69:01ESIMVLWRA0.99280.9122918
BAZ1B-METchr772912827chr7116435709910HLA-C07:01GRRESIMVL0.99050.7266615
BAZ1B-METchr772912827chr7116435709910HLA-B27:10RRESIMVLW0.98990.8939716
BAZ1B-METchr772912827chr7116435709910HLA-B27:08RRESIMVLW0.9780.7315716
BAZ1B-METchr772912827chr7116435709910HLA-B39:31GRRESIMVL0.97530.867615
BAZ1B-METchr772912827chr7116435709910HLA-C07:01RRESIMVLW0.97390.7432716
BAZ1B-METchr772912827chr7116435709910HLA-C07:17GRRESIMVL0.92840.9691615
BAZ1B-METchr772912827chr7116435709910HLA-C07:02GRRESIMVL0.89410.9614615
BAZ1B-METchr772912827chr7116435709910HLA-B27:09RRESIMVLW0.86660.8137716
BAZ1B-METchr772912827chr7116435709910HLA-C06:08GRRESIMVL0.85770.9898615
BAZ1B-METchr772912827chr7116435709910HLA-C07:22GRRESIMVL0.7750.7197615
BAZ1B-METchr772912827chr7116435709910HLA-C07:04GRRESIMVL0.72560.9201615
BAZ1B-METchr772912827chr7116435709910HLA-C07:22RRESIMVLW0.60020.7601716
BAZ1B-METchr772912827chr7116435709910HLA-C06:06GRRESIMVL0.41460.9887615
BAZ1B-METchr772912827chr7116435709910HLA-B15:68GRRESIMVL0.22730.751615
BAZ1B-METchr772912827chr7116435709910HLA-C06:17GRRESIMVL0.20880.992615
BAZ1B-METchr772912827chr7116435709910HLA-C06:02GRRESIMVL0.20880.992615
BAZ1B-METchr772912827chr7116435709910HLA-B27:10RRESIMVLWR0.99670.8324717
BAZ1B-METchr772912827chr7116435709910HLA-B27:10GRRESIMVLWR0.98050.8152617
BAZ1B-METchr772912827chr7116435709910HLA-B18:03DEGRRESIMVL0.95660.8823415

Top

Potential FusionNeoAntigen Information of BAZ1B-MET in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
BAZ1B-MET_72912827_116435709.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
BAZ1B-METchr772912827chr7116435709910DRB1-0437ESIMVLWRAPLGADD924
BAZ1B-METchr772912827chr7116435709910DRB1-0473ESIMVLWRAPLGADD924
BAZ1B-METchr772912827chr7116435709910DRB1-1113RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1113RRESIMVLWRAPLGA722
BAZ1B-METchr772912827chr7116435709910DRB1-1117RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1152RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1189RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1192RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1204RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1209RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1377RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1404RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1405RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1406RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1408RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1411RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1412RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1418RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1420RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1423RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1428RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1429RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1431RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1431RRESIMVLWRAPLGA722
BAZ1B-METchr772912827chr7116435709910DRB1-1432RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1432RRESIMVLWRAPLGA722
BAZ1B-METchr772912827chr7116435709910DRB1-1434RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1435RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1445RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1452RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1455RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1456RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1459RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1461RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1464RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1465RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1465RRESIMVLWRAPLGA722
BAZ1B-METchr772912827chr7116435709910DRB1-1472RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1478RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1481RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1483RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1491RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1496RESIMVLWRAPLGAD823
BAZ1B-METchr772912827chr7116435709910DRB1-1504ESIMVLWRAPLGADD924
BAZ1B-METchr772912827chr7116435709910DRB1-1510ESIMVLWRAPLGADD924
BAZ1B-METchr772912827chr7116435709910DRB1-1521ESIMVLWRAPLGADD924
BAZ1B-METchr772912827chr7116435709910DRB5-0204ESIMVLWRAPLGADD924

Top

Fusion breakpoint peptide structures of BAZ1B-MET

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3094GRRESIMVLWRAPLBAZ1BMETchr772912827chr7116435709910

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BAZ1B-MET

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3094GRRESIMVLWRAPL-7.9962-8.1096
HLA-B14:023BVN3094GRRESIMVLWRAPL-5.70842-6.74372
HLA-B52:013W393094GRRESIMVLWRAPL-6.83737-6.95077
HLA-B52:013W393094GRRESIMVLWRAPL-4.4836-5.5189
HLA-A11:014UQ23094GRRESIMVLWRAPL-10.0067-10.1201
HLA-A11:014UQ23094GRRESIMVLWRAPL-9.03915-10.0745
HLA-A24:025HGA3094GRRESIMVLWRAPL-6.56204-6.67544
HLA-A24:025HGA3094GRRESIMVLWRAPL-5.42271-6.45801
HLA-B44:053DX83094GRRESIMVLWRAPL-7.85648-8.89178
HLA-B44:053DX83094GRRESIMVLWRAPL-5.3978-5.5112
HLA-A02:016TDR3094GRRESIMVLWRAPL-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of BAZ1B-MET

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
BAZ1B-METchr772912827chr7116435709415DEGRRESIMVLAGGATGAAGGAAGGAGAGAGAGTATTATGGTCC
BAZ1B-METchr772912827chr7116435709515EGRRESIMVLATGAAGGAAGGAGAGAGAGTATTATGGTCC
BAZ1B-METchr772912827chr7116435709615GRRESIMVLAAGGAAGGAGAGAGAGTATTATGGTCC
BAZ1B-METchr772912827chr7116435709616GRRESIMVLWAAGGAAGGAGAGAGAGTATTATGGTCCTTT
BAZ1B-METchr772912827chr7116435709617GRRESIMVLWRAAGGAAGGAGAGAGAGTATTATGGTCCTTTGGC
BAZ1B-METchr772912827chr7116435709715RRESIMVLGAAGGAGAGAGAGTATTATGGTCC
BAZ1B-METchr772912827chr7116435709716RRESIMVLWGAAGGAGAGAGAGTATTATGGTCCTTT
BAZ1B-METchr772912827chr7116435709717RRESIMVLWRGAAGGAGAGAGAGTATTATGGTCCTTTGGC
BAZ1B-METchr772912827chr7116435709816RESIMVLWGGAGAGAGAGTATTATGGTCCTTT
BAZ1B-METchr772912827chr7116435709918ESIMVLWRAGAGAGAGTATTATGGTCCTTTGGCGTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
BAZ1B-METchr772912827chr7116435709722RRESIMVLWRAPLGAGAAGGAGAGAGAGTATTATGGTCCTTTGGCGTGCTCCTCTGGGAG
BAZ1B-METchr772912827chr7116435709823RESIMVLWRAPLGADGGAGAGAGAGTATTATGGTCCTTTGGCGTGCTCCTCTGGGAGCTG
BAZ1B-METchr772912827chr7116435709924ESIMVLWRAPLGADDGAGAGAGTATTATGGTCCTTTGGCGTGCTCCTCTGGGAGCTGATG

Top

Information of the samples that have these potential fusion neoantigens of BAZ1B-MET

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADBAZ1B-METchr772912827ENST00000339594chr7116435709ENST00000318493TCGA-BR-8080-01A

Top

Potential target of CAR-T therapy development for BAZ1B-MET

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneMETchr7:72912827chr7:116435709ENST0000043611709933_9550765.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to BAZ1B-MET

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to BAZ1B-MET

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource